Compare Vanguard Real Estate Index Fund ETF (VNQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Real Estate Index Fund ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Real Estate Index Fund ETF trades at $97.17, while Vertex Pharmaceuticals Incorporated trades at $526.93 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| VNQ | VRTX | |
|---|---|---|
52-Week High | $100.95 | $529.65 |
52-Week Low | $87.00 | $376.62 |
Market Cap | — | $134.25B |
Sector | — | Health |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQ (Vanguard Real Estate ETF) trades at $96.745, down 0.38% on the day amid a bearish technical signal. The ETF shows mixed momentum with oversold short-term RSI readings but bearish moving averages. Recent institutional selling activity from firms like Bank of America and City Holding Co. indicates cautious positioning in the real estate sector. The fund's dividend yield remains a key attraction for income-focused investors.
The outlook for VNQ is challenged by rising interest rate sensitivity and institutional outflows, though the oversold RSI suggests potential for near-term stabilization. Investors should weigh the ETF's low expense ratio and U.S. REIT diversification against sector-specific headwinds including commercial real estate pressures and economic uncertainty.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
